AZD 6703

Drug Profile

AZD 6703

Alternative Names: AZD-6703

Latest Information Update: 31 Jul 2007

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antirheumatics
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 31 Jul 2007 Discontinued - Phase-I for Rheumatoid arthritis (unspecified route)
  • 01 Feb 2007 Phase-I clinical trials in Rheumatoid arthritis (unspecified route)
  • 04 Jul 2006 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top